nach oben

European Journal of Pediatrics

Erschienen in:

01.12.2008 | Original Paper

The health and economic burden of rotavirus disease in Belgium

verfasst von: Joke Bilcke, Pierre Van Damme, Frank De Smet, Germaine Hanquet, Marc Van Ranst, Philippe Beutels

Erschienen in: European Journal of Pediatrics | Ausgabe 12/2008

Einloggen, um Zugang zu erhalten

Abstract

For health economic evaluations of rotavirus vaccination, estimates of the health and cost burden of rotavirus are required. Due to differences in health care systems and surveillance organisations, this is difficult to achieve by imputing estimates from one country to others. This study aimed to estimate the burden of rotavirus disease in Belgium. In children younger than 7 years of age, rotavirus is predicted to account annually for about 5,600 hospitalisations (676:100,000 children); 26,800 outpatient, general practitioner and paediatrician visits; and about 44,600 episodes for which no medical care is sought. This burden is estimated to represent direct costs of 7.7 million € and indirect costs of 12.8 million €. Rotavirus disease causes a substantial health and economic burden in Belgium.

ZebraZone European Research & Service Center, Het absenteïsme in België (2005) (http://www.zebrazone.be/ZebraZine/ZZineTXT/attach/White%20Paper%20Absenteisme%202005%20NL%20GRH.pdf)

Araujo EC, Clemens SA, Oliveira CS, Justino MC, Rubio P, Gabbay YB, Silva VB, Mascarenhas JD, Noronha VL, Clemens R, Gusmao RH, Sanchez N, Monteiro TA, Linhares AC (2007) Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. J Pediatr (Rio J) 83(3):217–224CrossRef

Beutels P, Van Damme P, Oosterhuis-Kafeja F (2006) Effects and costs of pneumococcal conjugate vaccination of Belgian children. KCE reports vol33C http://www.kce.fgov.be/index_en.aspx?SGREF=5220&CREF=8068)

Beutels P, Van Damme P, Van Casteren V, Gay NJ, De Schrijver K, Meheus A (2002) The difficult quest for data on “vanishing” vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium). Vaccine 20(29–30):3551–3559PubMedCrossRef

Bilcke J, Beutels P, De Smet F, Hanquet G, Van Ranst M, Van Damme P (2007) Cost-effectiveness analysis of rotavirus vaccination of Belgian infants. KCE reports vol54C http://www.kce.fgov.be/index_en.aspx?ID=0&SGREF=9152&CREF=9405)

Bilcke J, Van Damme P, Beutels P Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and ‘no medical care’ disease impact in Belgium. submitted

Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ, Bauder J, Boslego JW, Heaton PM (2007) Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 119(1):11–18PubMedCrossRef

Briggs A, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation. Oxford University Press, New York

de Zoysa I, Feachem RG (1985) Interventions for the control of diarrhoeal diseases among young children: rotavirus and cholera immunization. Bull W H O 63(3):569–583PubMed

10.

Dennehy PH (2007) Rotavirus vaccines-an update. Vaccine 25(16):3137–3141PubMedCrossRef

11.

Fruhwirth M, Heininger U, Ehlken B, Petersen G, Laubereau B, Moll-Schuler I, Mutz I, Forster J (2001) International variation in disease burden of rotavirus gastroenteritis in children with community- and nosocomially acquired infection. Pediatr Infect Dis J 20(8):784–791PubMed

12.

Giaquinto C, Van Damme P, Huet F, Gothefors L, Van der Wielen M (2007) Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: The REVEAL Study. J Infect Dis 195(Suppl 1):S36–S44PubMedCrossRef

13.

Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK, Widdowson MA, Jiang B, Gentsch JR (2006) Rotavirus vaccines: current prospects and future challenges. Lancet 368(9532):323–332PubMedCrossRef

14.

Gleizes O, Desselberger U, Tatochenko V, Rodrigo C, Salman N, Mezner Z, Giaquinto C, Grimprel E (2006) Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediatr Infect Dis J 25(1 Suppl):S12–S21PubMed

15.

Gurwith M, Wenman W, Hinde D, Feltham S, Greenberg H (1981) A prospective study of rotavirus infection in infants and young children. J Infect Dis 144(3):218–224PubMed

16.

Harris JP, Jit M, Cooper D, Edmunds WJ (2007) Evaluating rotavirus vaccination in England and Wales Part I. Estimating the burden of disease. Vaccine 25(20):3962–3970PubMedCrossRef

17.

Lorgelly PK, Joshi D, Iturriza Gomara M, Flood C, Hughes CA, Dalrymple J, Gray J, Mugford M (2007) Infantile gastroenteritis in the community: a cost-of-illness study. Epidemiol Infect 136(1):34–43PubMed

18.

Lorgelly PK, Joshi D, Iturriza Gómara M, Gray J, Mugford M (2007) Exploring the cost-effectiveness of an immunisation programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 136(1):44–55PubMed

19.

Newall AT, Beutels P, Macartney K, Wood J, MacIntyre R (2007) The cost-effectiveness of rotavirus vaccination in Australia. Vaccine 25(52):8851–8860

20.

Newall AT, MacIntyre R, Wang H, Hull B, Macartney K (2006) Burden of severe rotavirus disease in Australia. J Paediatr Child Health 42(9):521–527PubMedCrossRef

21.

Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI (2003) Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 9(5):565–572PubMed

22.

Phua KB, Quak SH, Lee BW, Emmanuel SC, Goh P, Han HH, De Vos B, Bock HL (2005) Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. J Infect Dis 192(Suppl 1):S6–S16PubMedCrossRef

23.

Piednoir E, Bessaci K, Bureau-Chalot F, Sabouraud P, Brodard V, Andreoletti L, Bajolet O (2003) Economic impact of healthcare-associated rotavirus infection in a paediatric hospital. J Hosp Infect 55(3):190–195PubMedCrossRef

24.

Raes M, Aerssens P, Alliet P, Gillis P, Verjans MP, Mewis A (2008) Rotavirus gastroenteritis: epidemiological data from a regional hospital in Belgium. Eur J Pediatr 167(1):71–73PubMedCrossRef

25.

Rodriguez WJ, Kim HW, Brandt CD, Schwartz RH, Gardner MK, Jeffries B, Parrott RH, Kaslow RA, Smith JI, Kapikian AZ (1987) Longitudinal study of rotavirus infection and gastroenteritis in families served by a pediatric medical practice: clinical and epidemiologic observations. Pediatr Infect Dis J 6(2):170–176PubMedCrossRef

26.

Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, Lopez P, Macias-Parra M, Ortega-Barria E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavia-Ruz N, Salmeron J, Ruttimann R, Tinoco JC, Rubio P, Nunez E, Guerrero ML, Yarzabal JP, Damaso S, Tornieporth N, Saez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O’Ryan M (2006) Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354(1):11–22PubMedCrossRef

27.

Salinas B, Perez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzabal JP, Cervantes Y, Costa Clemens S, Damaso S, Hardt K, De Vos B (2005) Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 24(9):807–816PubMedCrossRef

28.

Soriano-Gabarro M, Mrukowicz J, Vesikari T, Verstraeten T (2006) Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 25(1 Suppl):S7–S11PubMed

29.

Stebbins S (2007) Rotavirus: disease and vaccine update, 2007. J Fam Pract 56(2 Suppl Vaccines):S6–S11PubMed

30.

Thuret A, Patural H, Berthelot P, Benzait F, Martin I, Jusot JF, Teyssier G, Fabry J, Pozzetto B (2004) Prospective follow-up of hospital-acquired diarrhoea in 28 paediatric wards of the south-east part of France during a winter season. Pathol Biol (Paris) 52(3):131–137

31.

Van Casteren V, Bossuyt N (2002) Survey site visit Belgium July 15th 2002. Belgian Sentinel Network of General Practitioners

32.

Van Damme P, Giaquinto C, Huet F, Gothefors L, Maxwell M, Van der Wielen M (2007) Multicenter Prospective Study of the Burden of Rotavirus Acute Gastroenteritis in Europe, 2004–2005: The REVEAL Study. J Infect Dis 195(Suppl 1):S4–S16PubMedCrossRef

33.

Van Damme P, Van der Wielen M, Ansaldi F, Desgrandchamps D, Domingo JD, Sanchez FG, Gray J, Haditsch M, Johansen K, Lorgelly P, Lorrot M, Parez N, Reschke V, Rose M (2006) Rotavirus vaccines: considerations for successful implementation in Europe. Lancet Infect Dis 6(12):805–812PubMedCrossRef

34.

Vandenberghe H Estimation de la représentativité nationale du réseau des laboratoires vigies. Proceedings of the 20th seminary “Diagnosis and surveillance of infectious diseases” SIPH 2004:19–27 http://www.iph.fgov.be/epidemio/epifr/plabfr/semfr/sem20.pdf)

35.

Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, Glass RI, Estes MK, Pickering LK, Ruiz-Palacios GM (1996) Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 335(14):1022–1028PubMedCrossRef

36.

Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, Ward RL, Schodel F, Karvonen A, Drummond JE, DiNubile MJ, Heaton PM (2006) Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 24(22):4821–4829PubMedCrossRef

37.

Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Bouckenooghe A (2007) Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 370(9601):1757–1763PubMedCrossRef

38.

Vesikari T, Karvonen A, Puustinen L, Zeng SQ, Szakal ED, Delem A, De Vos B (2004) Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 23(10):937–943PubMedCrossRef

39.

Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O’Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM (2006) Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354(1):23–33PubMedCrossRef

40.

Widdowson MA, Meltzer MI, Zhang X, Bresee JS, Parashar UD, Glass RI (2007) Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 119(4):684–697PubMedCrossRef

Titel: The health and economic burden of rotavirus disease in Belgium
verfasst von: Joke Bilcke
Pierre Van Damme
Frank De Smet
Germaine Hanquet
Marc Van Ranst
Philippe Beutels
Publikationsdatum: 01.12.2008
Verlag: Springer-Verlag
Erschienen in: European Journal of Pediatrics / Ausgabe 12/2008
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-008-0684-3

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The health and economic burden of rotavirus disease in Belgium

Abstract

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2008

Neuroglial heterotopia causing neonatal airway obstruction: presentation, management, and literature review

Defining chronic diseases and health conditions in childhood (0–18 years of age): national consensus in the Netherlands

Clinical features and prognoses of 23 patients with chronic granulomatous disease followed for 21 years by a single hospital in Japan

Increased heme oxygenase-1 expression in premature infants with respiratory distress syndrome

Outbreaks of human coronavirus in a paediatric and neonatal intensive care unit

Splenic infarction in a patient hereditary spherocytosis, protein C deficiency and acute infectious mononucleosis

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie